HONG KONG – Dong-A ST. Co. Ltd., an 84-year-old South Korean pharmaceutical company, recently inked two separate licensing agreements with Nasdaq-listed Tobira Therapeutics Inc., as a further sign that Korean firms are reaching deeper into the global biopharma scene through licensing agreements with multinationals.
HONG KONG – South Korea's oldest and most respected pharmaceutical company, Yuhan Co. Ltd., is looking to move more aggressively into the global biopharma scene by striking up partnerships with U.S.-based companies that have larger global presences.
HONG KONG – South Korea's oldest and most respected pharmaceutical company, Yuhan Co. Ltd., is looking to move more aggressively into the global biopharma scene by striking up partnerships with U.S.-based companies that have larger global presences.
HONG KONG – South Korea’s Gtreebnt Co. Ltd., a firm that started out researching and developing software, is expanding its drug pipeline, most recently through a deal with a U.S. medical research foundation to develop a product for a lethal form of brain cancer.
HONG KONG – South Korea’s Gtreebnt Co. Ltd., a firm that started out researching and developing software, is expanding its drug pipeline, most recently through a deal with a U.S. medical research foundation to develop a product for a lethal form of brain cancer.
HONG KONG – A green light to launch clinical trials in Canada for one of its leading biosimilar products will give South Korean company Alteogen Inc. and its Brazilian partner a boost on the global market.
